Early identification of golimumab-treated patients with higher likelihood of long-term retention
BackgroundThe early identification of patients’ profiles most likely to respond to and maintain long-term therapy with a biological drug can have clinical and cost-effectiveness implications.ObjectivesTo evaluate the utility of an innovative approach for early identification of patient profiles asso...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-04-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1359571/full |
| _version_ | 1797213062690766848 |
|---|---|
| author | Alicia García-Dorta Enrique González-Dávila Marta Sánchez-Jareño Luis Cea-Calvo Manuel Pombo-Suárez Fernando Sánchez-Alonso Isabel Castrejón Federico Díaz-González Federico Díaz-González Federico Díaz-González |
| author_facet | Alicia García-Dorta Enrique González-Dávila Marta Sánchez-Jareño Luis Cea-Calvo Manuel Pombo-Suárez Fernando Sánchez-Alonso Isabel Castrejón Federico Díaz-González Federico Díaz-González Federico Díaz-González |
| author_sort | Alicia García-Dorta |
| collection | DOAJ |
| description | BackgroundThe early identification of patients’ profiles most likely to respond to and maintain long-term therapy with a biological drug can have clinical and cost-effectiveness implications.ObjectivesTo evaluate the utility of an innovative approach for early identification of patient profiles associated with long-term persistence of golimumab, a tumour necrosis factor inhibitor, in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (SpA) under real-world conditions.DesignRetrospective non-interventional database analysis.MethodsKaplan-Meier curves of golimumab retention over 8 years from the BIOBADASER registry, overall and by indication, were analysed using a novel approach (a two-phase decay model) to identify the point at which the golimumab retention curve shifted from rapid (indicating high golimumab discontinuation rate) to slow decay (low discontinuation rate). Factors associated with golimumab retention at these time points were identified using Cox regression, and retention rates for different patient profiles were calculated.Results885 patients were included. The golimumab retention curve shifted from rapid to slow decay at month 10 for the overall population (retention rate: 73.4%), at month 24 for RA patients (retention: 45.0%), and at month 8 for SpA, including axial SpA and PsA (81.6%). Factors associated with golimumab discontinuation at these early points were, overall, similar to those previously identified at year 8 (RA diagnosis, golimumab as second- or third-line of biological therapy, disease activity over the median and treatment with corticosteroids at golimumab initiation, advanced age [in RA], and female gender [in SpA]).ConclusionWith this novel approach, the factors associated with long-term retention were identified in the initial period of rapid discontinuation of golimumab. |
| first_indexed | 2024-04-24T10:52:18Z |
| format | Article |
| id | doaj.art-9928690062dd4e5db5b0704042a69a76 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-24T10:52:18Z |
| publishDate | 2024-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-9928690062dd4e5db5b0704042a69a762024-04-12T11:00:33ZengFrontiers Media S.A.Frontiers in Immunology1664-32242024-04-011510.3389/fimmu.2024.13595711359571Early identification of golimumab-treated patients with higher likelihood of long-term retentionAlicia García-Dorta0Enrique González-Dávila1Marta Sánchez-Jareño2Luis Cea-Calvo3Manuel Pombo-Suárez4Fernando Sánchez-Alonso5Isabel Castrejón6Federico Díaz-González7Federico Díaz-González8Federico Díaz-González9Departamento de Reumatología, Hospital Universitario de Canarias, Santa Cruz de Tenerife, SpainDepartamento de Matemáticas, Estadística e Investigación Operativa, Instituto de Matemáticas y Aplicaciones de la Universidad de La Laguna (IMAULL), Universidad de La Laguna, Santa Cruz de Tenerife, SpainMedical Affairs, MSD Spain, Madrid, SpainMedical Affairs, MSD Spain, Madrid, SpainDepartamento de Reumatología, Complejo Hospital Universitario de Santiago de Compostela, La Coruña, SpainUnidad de Investigación de la Sociedad Española de Reumatología (UI-SER), Madrid, SpainDepartamento de Reumatología, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Hospital Universitario Gregorio Marañon, Universidad Complutense de Madrid, Madrid, SpainDepartamento de Reumatología, Hospital Universitario de Canarias, Santa Cruz de Tenerife, SpainDepartamento de Medicina Interna, Dermatología y Psiquiatría, Universidad de La Laguna, Santa Cruz de Tenerife, SpainInstituto de Tecnologías Biomédicas (ITB), Universidad de La Laguna, Santa Cruz de Tenerife, SpainBackgroundThe early identification of patients’ profiles most likely to respond to and maintain long-term therapy with a biological drug can have clinical and cost-effectiveness implications.ObjectivesTo evaluate the utility of an innovative approach for early identification of patient profiles associated with long-term persistence of golimumab, a tumour necrosis factor inhibitor, in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (SpA) under real-world conditions.DesignRetrospective non-interventional database analysis.MethodsKaplan-Meier curves of golimumab retention over 8 years from the BIOBADASER registry, overall and by indication, were analysed using a novel approach (a two-phase decay model) to identify the point at which the golimumab retention curve shifted from rapid (indicating high golimumab discontinuation rate) to slow decay (low discontinuation rate). Factors associated with golimumab retention at these time points were identified using Cox regression, and retention rates for different patient profiles were calculated.Results885 patients were included. The golimumab retention curve shifted from rapid to slow decay at month 10 for the overall population (retention rate: 73.4%), at month 24 for RA patients (retention: 45.0%), and at month 8 for SpA, including axial SpA and PsA (81.6%). Factors associated with golimumab discontinuation at these early points were, overall, similar to those previously identified at year 8 (RA diagnosis, golimumab as second- or third-line of biological therapy, disease activity over the median and treatment with corticosteroids at golimumab initiation, advanced age [in RA], and female gender [in SpA]).ConclusionWith this novel approach, the factors associated with long-term retention were identified in the initial period of rapid discontinuation of golimumab.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1359571/fullgolimumabtreatment retentionrheumatoid arthritisaxial spondyloarthritispsoriatic arthritisbiological therapy |
| spellingShingle | Alicia García-Dorta Enrique González-Dávila Marta Sánchez-Jareño Luis Cea-Calvo Manuel Pombo-Suárez Fernando Sánchez-Alonso Isabel Castrejón Federico Díaz-González Federico Díaz-González Federico Díaz-González Early identification of golimumab-treated patients with higher likelihood of long-term retention Frontiers in Immunology golimumab treatment retention rheumatoid arthritis axial spondyloarthritis psoriatic arthritis biological therapy |
| title | Early identification of golimumab-treated patients with higher likelihood of long-term retention |
| title_full | Early identification of golimumab-treated patients with higher likelihood of long-term retention |
| title_fullStr | Early identification of golimumab-treated patients with higher likelihood of long-term retention |
| title_full_unstemmed | Early identification of golimumab-treated patients with higher likelihood of long-term retention |
| title_short | Early identification of golimumab-treated patients with higher likelihood of long-term retention |
| title_sort | early identification of golimumab treated patients with higher likelihood of long term retention |
| topic | golimumab treatment retention rheumatoid arthritis axial spondyloarthritis psoriatic arthritis biological therapy |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1359571/full |
| work_keys_str_mv | AT aliciagarciadorta earlyidentificationofgolimumabtreatedpatientswithhigherlikelihoodoflongtermretention AT enriquegonzalezdavila earlyidentificationofgolimumabtreatedpatientswithhigherlikelihoodoflongtermretention AT martasanchezjareno earlyidentificationofgolimumabtreatedpatientswithhigherlikelihoodoflongtermretention AT luisceacalvo earlyidentificationofgolimumabtreatedpatientswithhigherlikelihoodoflongtermretention AT manuelpombosuarez earlyidentificationofgolimumabtreatedpatientswithhigherlikelihoodoflongtermretention AT fernandosanchezalonso earlyidentificationofgolimumabtreatedpatientswithhigherlikelihoodoflongtermretention AT isabelcastrejon earlyidentificationofgolimumabtreatedpatientswithhigherlikelihoodoflongtermretention AT federicodiazgonzalez earlyidentificationofgolimumabtreatedpatientswithhigherlikelihoodoflongtermretention AT federicodiazgonzalez earlyidentificationofgolimumabtreatedpatientswithhigherlikelihoodoflongtermretention AT federicodiazgonzalez earlyidentificationofgolimumabtreatedpatientswithhigherlikelihoodoflongtermretention |